Skip to main content

Table 3 Adverse events and laboratory abnormality during the treatment period

From: Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study

Adverse events Clinical events (n = 10) [n (%)]
  Any grade ≥Grade 3
Diarrhea 4 (13.3) 0
Headache 2 (6.7) 0
Bloating 2 (6.7) 0
Fatigue 1 (3.3) 0
ALT increased 1 (3.3) 0